NL
CRSP icon

NWAM LLC’s CRISPR Therapeutics CRSP Stock Holding History

NWAM LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,173
Closed -$436K – 689
2026
Q1 		$436K Sell
9,173
-52,670
-85% -$2.78M 0.03% 434
2025
Q4 		$3.38M Sell
61,843
-39,926
-39% -$2.39M 0.19% 117
2025
Q3 		$7.53M Buy
101,769
+83,454
+456% +$4.79M 0.41% 52
2025
Q2 		$1.03M Buy
+18,315
New +$709K 0.06% 261

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

NWAM LLC's CRSP Position: Q2 2026 in Review

NWAM LLC sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 9,173 shares — an estimated $436K sold.

NWAM LLC first reported a position in CRSP in Q2 2025 and held it in 4 quarters. The position peaked at $7.53M in Q3 2025. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • NWAM LLC reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • NWAM LLC sold 9,173 CRISPR Therapeutics shares in Q2 2026, an estimated $436K.
  • NWAM LLC first reported a position in CRISPR Therapeutics in Q2 2025 and held it in 4 quarters.
  • NWAM LLC's CRISPR Therapeutics position peaked at $7.53M in Q3 2025.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on NWAM LLC's 13F filing for Q2 2026, filed 23 Jul 2026.